- Associated Press•7 hours ago
Vertex Pharmaceuticals Inc. on Tuesday reported a loss of $41.8 million in its third quarter. On a per-share basis, the Boston-based company said it had a loss of 17 cents. Earnings, adjusted for stock ...
- The Wall Street Journal•9 hours ago
Vertex Pharmaceuticals cut its quarterly loss in half as sales rose 34%, driven by its cystic fibrosis drugs Kalydeco and Orkambi.
- TheStreet.com•9 hours ago
Vertex hopes the new drugs will improve on the efficacy and tolerability of Orkambi, the first combination therapy approved for cystic fibrosis in 2015.
Vertex Pharmaceuticals Incorporated (VRTX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Day's Range||77.43 - 79.75|
|52wk Range||75.90 - 134.71|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-69.41|
|Avg Vol (3m)||1,423,026|
|Dividend & Yield||N/A (N/A)|